Your Body Already Makes a Protein That Reverses Brain Aging. It Just Stops Making Enough.

A protein your body already produces reversed cognitive decline in old mice within hours of a single injection. It's called klotho. Levels drop as you age. And a biotech company just raised $35 million to test whether injecting it back into humans can do what it did in mice.

That's the short version. The long version is stranger.

An Accidental Discovery Named After a Goddess

In 1997, Japanese researcher Makoto Kuro-o was studying a completely unrelated gene mutation when he stumbled on something odd. Mice with a disrupted version of one particular gene aged catastrophically — multiple organ failure, death at two months instead of the usual two and a half years. They looked ancient.

He named the gene klotho, after the Greek goddess of fate who spins the thread of life.

It took years to figure out what the protein actually does. It's produced mainly in the kidneys and brain. It regulates calcium, phosphorus, and vitamin D. It helps control inflammation and cellular stress responses. And it declines — steadily, predictably — as humans age.

Here's where it gets interesting. The decline isn't just a side effect of getting older. It might be one of the causes.

What One Injection Did to Old Mice

Dr. Dena Dubal, a neurologist at UC San Francisco, published a study in Nature showing that injecting klotho into aging mice improved their synaptic plasticity and spatial memory within days. Old mice started performing memory tasks at levels comparable to young ones.

One injection. Not a course of treatment. Not months of supplements. A single dose triggered what appears to be a cascade of downstream effects — the protein doesn't just patch a deficit, it seems to restart the brain's ability to form and strengthen neural connections.

That was remarkable enough. Then Dubal's team found something even more provocative.

The Alzheimer's Shield Nobody Expected

People naturally carry different genetic variants of klotho. Some produce more. Some produce less. Dubal's lab published findings in Cell Reports showing that people with a variant producing higher klotho levels performed better on cognitive tests as they aged.

The correlation held across demographics. That alone would've been noteworthy.

But it also held in carriers of APOE4 — the strongest known genetic risk factor for Alzheimer's disease. A meta-analysis across 22 cohorts at Stanford found that APOE4 carriers with the protective klotho variant were 35% less likely to develop mild cognitive impairment or Alzheimer's.

Let that sit for a second. The protein didn't just help healthy brains stay sharp. It appeared to offer protection precisely where every other intervention has failed. Alzheimer's drugs have an 99% failure rate in clinical trials. Klotho protected against it before it started.

$35 Million and a Q4 2026 Deadline

The commercial journey has been bumpy. Unity Biotechnology licensed klotho from UCSF back in 2019. They worked on it for several years in preclinical models before eventually handing the program to Jocasta Neuroscience, a startup co-founded by Dubal herself.

In August 2025, Jocasta raised $35 million in a Series A round to develop JN-0413, their lead klotho compound, through Phase 1 trials. The plan: submit an Investigational New Drug application to the FDA by Q4 2026. If approved, they'll run single ascending dose and multiple ascending dose studies in healthy older adults.

The initial trials will measure safety and dosing. But researchers will also track cognitive performance on standardised tests over 90 days following a single subcutaneous injection. If results are promising, Phase 2 could begin as early as 2027.

The $50 Billion Gap

Americans over 50 spend billions annually on brain health supplements — ginkgo, lion's mane, nootropics, subscription apps. The global brain health supplement market hit $50 billion. Most of it has thin evidence behind it.

Meanwhile, the most promising cognitive-protection molecule identified in decades is something the body already makes. It doesn't need to cross the blood-brain barrier from a pill. It's already there. It just needs to be topped up.

That's an oversimplification, obviously. Mouse-to-human translation has a long, humbling history of failure. What works in a rodent model routinely disappoints in human trials. Dosing, delivery, side effects — all unknowns. And klotho's mechanism isn't fully understood. Scientists know it enhances NMDA receptor function in the brain, improving synaptic transmission. They don't know exactly why lower circulating levels in the blood correlate with longer survival in some studies but higher brain levels correlate with better cognition.

Why This Matters Beyond the Lab

Dementia affects 55 million people worldwide. That number is projected to hit 139 million by 2050. Current treatments — the new wave of amyloid-clearing drugs like lecanemab and donanemab — slow decline modestly but come with brain swelling risks and cost $26,000 a year.

Klotho works on a different mechanism entirely. It doesn't target amyloid plaques or tau tangles. It enhances the brain's own repair systems. If it works in humans, it could complement existing approaches or — in the most optimistic scenario — offer prevention rather than damage control.

The IND filing is months away. The trial results are years away. But the science is already telling us something worth hearing: the body might contain its own cognitive repair kit. It just runs low at the worst possible time.

Whether Jocasta's compound can fix that is the $35 million question. We'll have the first clues by 2027.